NEXTBio Capital Management LP Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0002038158

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 22 positions · Total reported value $217.40M · Top-10 concentration 77.7% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 38.5% · 4 new · 4 cut · 2 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -4.2% · vs SPY -6.3% · Prev Value $217.40M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -3.2% · vs SPY -5.4% · Latest Value $229.71M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, NEXTBio Capital Management LP disclosed 22 equity positions with a combined reported value of $217.40M. The filing implies a focused portfolio: its ten largest positions account for 77.7% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were PTGX ($26.89M), STTK ($25.87M), CMPS ($25.13M). By sector, the heaviest allocations are Health Care 100.0%. Versus the prior quarter, allocation shifted toward Health Care (+16.0pp) and away from Other (-16.0pp).

Versus the prior quarter, NEXTBio Capital Management LP opened 4 new positions, trimmed 4 and fully exited 2, a turnover rate of 38.5% of positions. The portfolio's overlap with the prior quarter was 70% of names.

The largest new positions opened in Q2 2026 were PHVS ($3.74M), BIOA ($2.47M), LBRX ($2.22M).

Of the 2 positions fully exited versus the prior quarter, the largest were TERN ($31.87M), CMPX ($4.49M), OCS ($3.98M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • PHVS PHARVARIS N V · $3.74M
  • BIOA BIOAGE LABS INC · $2.47M
  • LBRX LB PHARMACEUTICALS INC · $2.22M

Fully Exited (vs previous quarter)

  • TERN TERNS PHARMACEUTICALS INC · prev qtr: $31.87M
  • CMPX COMPASS THERAPEUTICS INC · prev qtr: $4.49M
  • OCS OCULIS HOLDING AG · prev qtr: $3.98M
  • KALV KALVISTA PHARMACEUTICALS INC · prev qtr: $2.65M
  • SMMT SUMMIT THERAPEUTICS INC · prev qtr: $1.70M

Insider Transactions (Form 4)

Latest NEXTBio Capital Management LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

NEXTBio Capital Management LP, based in Austin, TX, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 22 positions worth $217.40M in total. HoldingsHub carries 3 quarters of its filings (Q4 2025–Q2 2026).

Firm Snapshot

  • Headquarters: AUSTIN, TX, United States
  • SEC registration: 801-136876 (status: Approved), registered 2026-07-23
  • Regulatory AUM (Form ADV): $305.21M as of 2026-07-07
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 6 private funds, of which 1 hedge funds
  • Website: nextbiocapital.com

Portfolio Structure

  • 22 positions · $217.40M reported value (Q2 2026)
  • Top 10 holdings = 77.7% of reported value
  • Largest position: PTGX (PROTAGONIST THERAPEUTICS INC) at 12.4%
  • Average position size: $9.88M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 3 new, 7 added, 4 reduced, 5 exited
  • 8 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: NEXTBio Capital Management LP appears to be maintaining a cautious approach with a slight preference for growth within the healthcare sector. The fund has reduced positions in some companies and increased in others, indicating a selective approach to capital allocation. 2. Key Moves: - Added: Shattuck Labs (STTK) by 18.3% and Oric Pharmaceuticals (ORIC) by 34.9%. These additions suggest a focus on potentially high-growth companies. - Reduced: Protagonist Therapeutics (PTGX) by 4.5% and Compass Pathways (CMPS) by 12.2%. The reduction in these positions could indicate concerns about their performance or market potential. - Added: Rhythm Pharmaceuticals (RYTM) and Palvela Therapeutics (PVLA) by 4.5% and 8.7% respectively, indicating a belief in their growth prospects. 3. Portfolio Structure: - Passive/Active: The fund seems to be active, as it is making changes to its holdings rather than maintaining a passive index-like approach. - Sector Bias: The fund is heavily biased towards the healthcare sector, reflecting a thematic focus on biotechnology and pharmaceuticals. - Risk Appetite: The addition of high-growth companies like Shattuck Labs and Oric Pharmaceuticals suggests a moderate to high risk appetite. 4. Per-Holding One-Liner: - PTGX: Biotechnology company focused on developing therapies for rare diseases. - STTK: Biotechnology company focused on developing treatments for neurological disorders. - CMPS: Biotechnology company focused on developing therapies for mental health conditions. - GPCR: Biotechnology company focused on developing therapies for neurological and psychiatric disorders. - VOR: Biotechnology company focused on developing therapies for cancer and other diseases. - RYTM: Biotechnology company focused on developing therapies for rare genetic disorders. - PVLA: Biotechnology company focused on developing therapies for rare genetic diseases. - XENE: Biotechnology company focused on developing therapies for rare genetic disorders. - ZBIO: Biotechnology company focused on developing therapies for rare genetic diseases. - ORIC: Biotechnology company focused on developing therapies for rare genetic diseases. 5. One-Sentence Style Summary: NEXTBio Capital Management LP maintained a selective approach to healthcare investments in Q2 2026, focusing on growth opportunities while cautiously reducing positions in some companies.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 219.33K $26.89M 12.37%
12.37%
Reduce
2 3.73M $25.87M 11.90%
11.90%
Add
3 1.78M $25.13M 11.56%
11.56%
Reduce
4 312.50K $16.77M 7.71%
7.71%
Add
5 889.16K $16.37M 7.53%
7.53%
Reduce
6 131.76K $14.63M 6.73%
6.73%
Add
7 89.91K $13.74M 6.32%
6.32%
Add
8 183.22K $11.06M 5.09%
5.09%
Hold
9 426.74K $10.83M 4.98%
4.98%
Hold
10 706.12K $7.65M 3.52%
3.52%
Add
11 1.79M $6.76M 3.11%
3.11%
Add
12 372.86K $6.71M 3.09%
3.09%
Hold
13 107.22K $6.23M 2.87%
2.87%
Add
14 131.07K $5.07M 2.33%
2.33%
Hold
15 1.31M $4.99M 2.30%
2.30%
Hold
16 52.66K $3.85M 1.77%
1.77%
Hold
17 108.06K $3.74M 1.72%
1.72%
New
18 183.36K $3.48M 1.60%
1.60%
Hold
19 100.73K $2.47M 1.14%
1.14%
New
20 68.25K $2.22M 1.02%
1.02%
New
21 119.06K $1.58M 0.73%
0.73%
Reduce
22 157.83K $1.36M 0.63%
0.63%
Hold

FAQ

What did NEXTBio Capital Management LP buy in 2026-Q2?

In its 2026-Q2 13F filing, NEXTBio Capital Management LP reported 22 equity positions worth $217.40M in aggregate; its largest disclosed positions were PTGX ($26.89M), STTK ($25.87M), CMPS ($25.13M).

How large is NEXTBio Capital Management LP's portfolio?

NEXTBio Capital Management LP reported $217.40M of long equity holdings across 22 positions as of 2026-Q2. Top-10 holdings account for 77.7% of reported value.

What is NEXTBio Capital Management LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/nextbio-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →